Posted by Michael Wonder on 12 Jul 2023
Renibus Therapeutics announces breakthrough therapy designation from US FDA for RBT-1 for the reduction in risk of post-operative complications in patients undergoing cardiothoracic surgery
11 July 2023 - RBT-1 is a first in class, pre-conditioning drug in the cardiothoracic surgery setting.
Renibus Therapeutics today announced that the US FDA has granted breakthrough therapy designation to RBT-1 for the reduction in risk of post-operative complications in patients undergoing cardiothoracic surgery, and confirmed its alignment with the Company's planned Phase 3 pivotal trial.
